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BACKGROUND: Asthma is one of the most common chronic diseases in the world, and previous studies have reported low levels of
control. Recent developments in the availability and use of online sources of information about asthma might add to patients’
knowledge and help improve control.
AIMS: To investigate whether asthma control has improved by assessing levels of symptoms, exacerbations and Global Initiative for
Asthma-deﬁned control in a real-life population of patients who use the Internet and social media, as well as evaluate patient
perception of control and attitudes to asthma.
METHODS: Online surveys were conducted among 8,000 patients with asthma (aged 18–50 years, ⩾ 2 prescriptions in the previous
2 years, use of social media) from 11 European countries.
RESULTS: Levels of asthma control were low: 45% of respondents had uncontrolled asthma. Acute exacerbations were common: 44%
of respondents reported having used oral steroids for asthma in the previous 12 months, 24% had visited an emergency department
and 12% had been hospitalised. More than 80% of respondents (overall, and among those with a history of exacerbations) considered
their asthma to be controlled. Of those who had an exacerbation requiring oral steroids, 75% regarded their asthma as not serious.
CONCLUSIONS: Asthma control in Europe remains poor; symptoms and exacerbations are common. Many patients regard their
asthma as controlled and not serious despite experiencing symptoms and exacerbations. There is a need to assess patients’ control,
risk and inhaler technique, and to ensure that patients are prescribed, and take, appropriate treatments.
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INTRODUCTION
Asthma is one of the most common chronic conditions in the
world; according to the Global Burden of Disease Study, asthma
caused more than 345,000 deaths worldwide in 2010.1,2 In Europe
alone, asthma affects 30 million people,2,3 and the cost of asthma
care in Europe is estimated at £18 billion per year; lost productivity
accounts for almost £10 billion of this.3,4
Asthma control in clinical practice is suboptimal despite
available therapies;5–7 over the last decade, European studies
have shown little apparent improvement in the levels of symptom
control.5,7 Poor asthma control is associated with increased risk of
exacerbations, debilitation, impaired quality of life, increased
health-care utilisation and reduced productivity.5,7,8 Asthma can
remain uncontrolled in patients prescribed regular therapy, who
may continue to experience exacerbations.7 Importantly, a history
of asthma exacerbations is a risk factor for future exacerbations;
hence, understanding predictive factors is important.9 Other risk
factors include poor asthma control and poor adherence.9,10
International guidelines, such as those produced by the Global
Initiative for Asthma (GINA), state that treatment should be based on
a patient’s level of asthma control deﬁned by daytime symptoms,
normal activities affected by symptoms, night-time awakenings and
reliever inhaler use.2 The incidence of asthma control in clinical
practice is considerably lower than the levels (up to 70%) reported in
many randomised controlled trials.11–13 This may be because
randomised controlled trials are not representative of real life,
because only a very small subset of patients from clinical practice
(1–2%) is eligible for inclusion,14 or because trial participation
inﬂuences participants’ behaviour (the ‘Hawthorne effect’).15
Many patients may overestimate their symptom control and
underestimate the severity of their condition, indicating that they
tolerate symptoms and lifestyle limitations.7,16 Patients may
describe symptoms more positively to their health-care profes-
sionals (HCPs) than they would when completing a validated
questionnaire. To develop effective asthma therapies and to
improve real-life outcomes, it is therefore important to under-
stand, and adapt to, different patients’ attitudes towards their
condition and to tailor treatments to their speciﬁc needs.2 This
requires effective communication, a valid assessment of control, a
clear understanding between patients and HCPs, and greater
patient knowledge about their condition.
Here, we report data from the REcognise Asthma and LInk to
Symptoms and Experience (REALISE) survey, conducted in
11 European countries among 8,000 individuals who use social
media—the largest and most recent survey of its kind.5,16–20 This
survey assessed symptoms and levels of asthma control in a real-
life setting and evaluated how symptoms and indicators of acute
exacerbations relate to guideline-deﬁned control and different
treatment levels; in addition, current asthma control was analysed
in relation to exacerbation history. Patients’ perceptions of asthma
control and symptoms were also explored. The data provide
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important new insights into patients’ attitudes and whether real-
life asthma control has improved in recent years.
MATERIALS AND METHODS
Survey design
This quantitative, questionnaire-based survey was designed to:
● assess symptoms, indicators of acute exacerbations and levels of
guideline-deﬁned control in a real-life population of patients who use
social media;
● compare asthma symptoms, exacerbations and control levels across
different treatment levels (reliever inhaler only, single-drug preventer
inhaler, combination preventer inhaler and combination preventer
inhaler plus oral pill);
● report the incidence of past exacerbations stratiﬁed by current asthma
control level;
● investigate respondents’ perceptions of asthma control in relation to
their guideline-deﬁned level of control and history of exacerbations; and
● explore attitudes of patients towards asthma and its management, and
investigate the sources of information preferred by patients who use
social media.
The survey was conducted online in 11 European countries (Austria,
Belgium, Finland, France, Germany, Italy, the Netherlands, Norway, Spain,
Sweden and the United Kingdom), between July and October 2012, by
Incite Marketing Planning Limited (London, UK), in accordance with the
Codes of Conduct of the Market Research Society, European Pharmaceu-
tical Marketing Research Association and Association of the British
Pharmaceutical Industry, and guidelines from the British Healthcare
Business Intelligence Association. Data were managed in accordance
with the Data Protection Act (UK, 1998). The survey was supported by
Mundipharma International Limited (Cambridge, UK).
Questionnaire development
The questionnaire was developed through a series of meetings with
experts in the ﬁeld and the authors, who provided input and advice on the
questions, methodology and structure of the survey. A cognitive testing
phase was conducted in Germany with six participants to ensure that
questions were unambiguous and to test the validity and consistency of
responses; minor amendments were made to clarify the questions.
Questionnaires took approximately 30min to complete.
Survey population
This survey was conducted among individuals aged 18–50 years who
conﬁrmed that they had been diagnosed with asthma by a doctor, had at
least two prescriptions for asthma in the previous 2 years and used social
media. Respondents who had participated in market research surveys
within the previous 3 months were excluded.
The survey population was drawn from validated consumer panels,
which were mainly recruited online (Watermelon Research, London, UK). In
Norway and Finland, recruitment was supplemented by press advertising.
Approximately 590,740 members of the general public (regardless of
asthma status) who had previously registered on consumer panels and had
agreed to take part in market research were sent an e-mail inviting them to
participate. The invitation described the survey as ‘health related’, but did
not mention asthma. Those who clicked the link to start the questionnaire
were asked screening questions to ensure that they had asthma and met
the other inclusion criteria (Figure 1); eligible participants were then able to
complete the full questionnaire. Upon completion of the survey,
respondents immediately received a reward in a points-based incentive
scheme. Of the 88,611 individuals who responded, the ﬁrst 38,894 were
excluded as soon as they failed a screening question; the process was
subsequently amended to streamline recruitment and enrolment, and all
other respondents (n= 49,717) answered all screening questions before
being excluded; this technical amendment did not affect the outcome of
the screening. The target survey population was 8,000; this sample size was
chosen to provide a sufﬁciently large and robust population across the
different countries. Additional respondents were not recruited once this
number was achieved.
Panels met the International Organization for Standardization 20252
quality standards; multiple panels were used to reduce potential bias.
Quality control measures (including cross-referencing of Internet
addresses) identiﬁed respondents registered on multiple panels; these
respondents were excluded.
Data analysis
Questionnaire responses were analysed for the total population;
answers relating to indicators of acute exacerbations and symptoms
were analysed by asthma control level and treatment type. Asthma
control was assessed using the four GINA criteria based on the questions
from the Helping Asthma in Real-life Patients initiative, which asked on
how many days in the previous 7 days respondents had day-time
symptoms, had awoken at night or had their normal activities affected by
asthma, and how many times they had used a reliever inhaler.21
Respondents’ perceptions of asthma were analysed by GINA-deﬁned
control level and exacerbations. Respondents were asked which treat-
ments they were currently taking: ‘reliever/rescue inhaler’, ‘preventer
inhaler’, ‘combination inhaler’, ‘oral treatment (pill)’ or ‘other asthma
medication’.
The relationship between indicators of asthma symptoms and exacer-
bations and GINA-deﬁned control was assessed using Pearson’s correlation
coefﬁcient (r). Correlations of r⩾ 0.6 were considered strong.
RESULTS
Respondent population
Of the 590,740 individuals invited to participate, 88,611 started
answering the questionnaire (response rate 15.0%); this
response rate is broadly consistent with those for previous
surveys. In total, 69,646 respondents did not meet the inclusion
criteria and were excluded; the most common reason was not
having asthma (98.3% (n= 68,479); Figure 1). After data
quality checks, 8,000 respondents were included in the ﬁnal
survey and data analysis and constituted the survey population
(Table 1).
Asthma control and symptoms
Overall, 20.1% of respondents had controlled asthma according to
the GINA criteria, 34.8% had partially controlled asthma and 45.1%
Questionnaires
started
(n= 88,611)
Respondents
completing
questionnaire
(n= 8,370)
Excluded
• Did not meet criteriaa (n=69,646)
 • Did not have asthma (n= 68,479)b 
 • Fewer than 2 prescriptions (n= 39,537)b
 • Not aged 18–50 years (n= 15,239)b
 • Do not use social media (n= 7,459)b
• Incomplete questionnaires (n= 4,560)
• National representation quota (n= 6,035)
Excluded
• Data cleaning quality checks (n= 370)
Respondents
included in
final survey
(n= 8,000)
Figure 1. Survey design. aParticipants were excluded if they failed
one or more screening questions (see Methods). bData shown for
individual answers to screening questions; 49,717 respondents
answered all screening questions before being screened and hence
the total number of reasons for exclusion exceeds 69,646.
REcognise Asthma and LInk to Symptoms and Experience
D Price et al
2
npj Primary Care Respiratory Medicine (2014) 14009 © 2014 Primary Care Respiratory Society UK /Macmillan Publishers Limited
had uncontrolled asthma (Table 2). Over half of the respondents
had awoken at night or had symptoms that interfered with daily
activities in the week before completing the survey. Overall, 44.0%
of respondents reported having used oral steroids for asthma in
the previous 12 months, 23.9% reported having visited an
emergency department and 11.7% reported having been
hospitalised overnight. Breathlessness was identiﬁed as the
symptom with the greatest impact (Figure 2).
Symptoms and exacerbations across control levels
Incidences of asthma symptoms and indicators of exacerbations
across asthma control levels are shown in Table 2. Some
respondents whose asthma was currently controlled according
to the GINA criteria reported a history of acute exacerbations in
the previous year: 42.3% used antibiotics, 23.7% required oral
steroids, 7.4% visited an emergency department and 1.6% had
been hospitalised overnight owing to asthma in the 12 months
before the survey.
Symptoms and indicators of acute exacerbations across treatment
levels
Table 3 presents GINA-deﬁned levels of asthma control, incidence
of symptoms and indicators of acute exacerbations stratiﬁed by
treatment level. Symptoms tended to be more common
among respondents prescribed maintenance therapy than among
those prescribed only a reliever inhaler (Table 3). The proportion
reporting indicators of acute exacerbations increased consistently
with treatment level. Notably, across all treatment levels,
half of the respondents had been prescribed a course of
antibiotics owing to their asthma and more than one-quarter
had required oral steroids in the previous 12 months. High levels
of reliever inhaler use (⩾10 times in the previous 7 days) were
most common among respondents prescribed a combination
preventer inhaler.
Respondents’ perceptions of asthma
Respondents’ perceptions of their asthma symptoms and control
are summarised in Table 4. Most did not regard themselves as
‘sick’, and many stated that they ignored their asthma to ‘feel
normal and ﬁt in’. More than 80% of respondents considered their
asthma to be controlled and over two-thirds did not regard their
condition as serious, even among those whose asthma was
uncontrolled according to the GINA criteria (Table 5). Similarly,
more than 80% of respondents who had experienced acute
exacerbations (oral steroid use, emergency department visits or
hospitalisations) in the previous year regarded their asthma as
controlled. Of those who considered their asthma controlled,
55.5% had had symptoms that interfered with normal activities
and 52.5% had awoken at night owing to asthma in the previous
week. Moreover, of those who regarded their asthma as not
serious, 19.5% reported an asthma-related emergency department
visit in the previous year.
Attitudes towards asthma and its management
The majority of respondents were fairly or very conﬁdent about
managing their asthma (91.7%) and felt they had ‘excellent’ or
‘good’ knowledge about its treatment (75.3%). Over half of any
respondents who stated that they had a preventer inhaler did not
use it every day as prescribed (Figure 3). The most common
reasons selected for non-adherence (base, n= 1,401) were not
seeing the need to take it (50.0%) or forgetting (18.6%). More than
one-quarter of respondents felt embarrassed about their inhaler,
and two out of ﬁve considered it a nuisance (Figure 4). Overall,
52.7% of respondents had not had their inhaler technique
checked by an HCP in the previous 12 months.
Sources of asthma information
Overall, 78.5% of respondents stated that they would consult their
HCP for information about asthma (Figure 5); moreover, 60.7%
Table 1. Respondent demographics and characteristics
Respondents
(N= 8,000)
Sex, n (%)
Female 4,918 (61.5)
Male 3,082 (38.5)
Age, years 34.7
Age range, years, n (%)
18–25 1,540 (19.3)
26–35 2,697 (33.7)
36–40 1,372 (17.2)
41–50 2,391 (29.9)
Country, n (%)
France 1,024 (12.8)
Spain 1,020 (12.8)
Italy 1,014 (12.7)
Germany 1,000 (12.5)
UK 1,000 (12.5)
Netherlands 855 (10.7)
Sweden 603 (7.5)
Finland 473 (5.9)
Austria 468 (5.9)
Belgium 303 (3.8)
Norway 240 (3.0)
Years since asthma diagnosis, n (%)a
1 or less 233 (3.3)
2–5 777 (11.0)
6–10 1,069 (15.1)
11 or more 5,014 (70.7)
Current smokers,b n (%) 1,820 (22.8)
Co-morbidities,c n (%)
Depression 1,083 (13.5)
High BP/hypertension 1,210 (15.1)
Diabetes 870 (10.9)
Rheumatoid arthritis 670 (8.4)
COPD 493 (6.2)
Heart disease 426 (5.3)
Cancer 221 (2.8)
Treatment type,d n (%)
None 359 (7.7)
Reliever inhaler only 1,419 (30.3)
Single-drug preventer inhaler (± reliever
inhaler)
1,923 (41.0)
Combination preventer inhaler (± reliever
inhaler)
754 (16.1)
Combination preventer inhaler plus oral
pill (± reliever inhaler)
234 (5.0)
Data are shown as means unless otherwise stated.
Abbreviations: BP, blood pressure; COPD, chronic obstructive pulmonary
disease.
an= 7,093.
bCombines answers for respondents who described themselves as ‘still
smoking’, as opposed to ‘never smoked tobacco’, ‘have tried tobacco in the
past, but don’t currently smoke’ and ‘used to smoke tobacco, but don’t
now’.
cSelf-reported by respondents as having been diagnosed by a doctor, in
response to the question: ‘Do you currently suffer from any of the
following illnesses, which have been diagnosed by a doctor?’.
dOnly respondents with an identiﬁable treatment were included
(n= 4,689).
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Table 2. Indicators of asthma symptoms and exacerbations overall and by GINA-deﬁned control levels
Overall (N= 8,000) GINA-deﬁned asthma control Correlation
with control, r
Controlled (n= 1,604) Partially controlled
(n= 2,785)
Uncontrolled (n= 3,611)
Control and indicators of symptoms
Days with symptomsa
None 1,622 (20.3) 1,037 (64.7) 544 (19.5) 41 (1.1)
⩾1 day 6,378 (79.7) 567 (35.3) 2,241 (80.5) 3,570 (98.9) 0.600b
⩾ 3 days 3,343 (41.8) 0 449 (16.1) 2,894 (80.1)
Normal activities affected by symptomsa
None 3,360 (42.0) 1,604 (100) 1,455 (52.2) 301 (8.3) 0.708b
⩾ 1 day 4,640 (58.0) 0 1,330 (47.8) 3,310 (91.7)
Night-time awakeninga
None 3,639 (45.5) 1,604 (100) 1,606 (57.7) 429 (11.9) 0.683b
⩾ 1 day 4,361 (54.5) 0 1,179 (42.3) 3,182 (88.1)
Reliever inhaler usea
Not used 2,143 (26.8) 1,083 (67.5) 894 (32.1) 166 (4.6) 0.679b
⩾ 1 time 5,509 (68.9) 407 (25.4) 1,738 (62.4) 3,364 (93.2)
⩾ 3 times 3,430 (42.9) 0 610 (21.9) 2,820 (78.1)
⩾ 10 times 518 (6.5) 0 85 (3.1) 433 (12.0)
Acute exacerbations
Oral steroid use for worsening asthmac
Not used 4,484 (56.1) 1,224 (76.3) 1,924 (69.1) 1,336 (37.0) 0.332
⩾ 1 course 3,516 (44.0) 380 (23.7) 861 (30.9) 2,275 (63.0)
Days off work/educationc,d
None 4,150 (62.5) 1,163 (85.7) 1,772 (77.1) 1,215 (40.8) 0.389
⩾ 1 day 2,485 (37.5) 194 (14.3) 525 (22.9) 1,766 (59.2)
Antibiotic use for an asthma-associated conditionc
None 3,033 (37.9) 925 (57.7) 1,250 (44.9) 858 (23.8) 0.278
⩾ 1 course 4,967 (62.1) 679 (42.3) 1,535 (55.1) 2,753 (76.2)
Emergency department visit due to asthmac
None 6,090 (76.1) 1,485 (92.6) 2,421 (86.9) 2,184 (60.5) 0.317
⩾ 1 visit 1,910 (23.9) 119 (7.4) 364 (13.1) 1,427 (39.5)
Overnight hospitalisation due to asthmac
None 7,066 (88.3) 1,579 (98.4) 2,695 (96.8) 2,792 (77.3) 0.284
⩾ 1 stay 934 (11.7) 25 (1.6) 90 (3.2) 819 (22.7)
Data are shown as n (%) of patients. Pearson’s correlation coefﬁcient (r) shows correlation between control and symptoms/exacerbations. P= 0.001 for all
correlations.
Abbreviation: GINA, Global Initiative for Asthma.
aIn the previous 7 days.
bStrong correlation.
cIn the previous 12 months.
dBase: overall, n= 6,635; controlled, n= 1,357; partially controlled, n= 2,297; uncontrolled, n= 2,981.
Ranked 1 Ranked 2 Ranked 3 Ranked 4 Ranked 5 This doesn’t affect me
Breathlessness
Coughing
Wheezing
Chest tightness
Night-time awakenings
4
7
7
16
23
29
20
18
15
7
9
13
17
19
26
18
20
20
18
15
24
21
21
16
11
15
19
17
16
20
0 20 10010 30 40 6050 70 80 90
Respondents (%)
Figure 2. Asthma symptoms with the greatest impact on respondents’ lives for the overall population. Q. Which asthma symptoms do you
ﬁnd affect you most? Place in order, with 1 having the most impact on your life and 5 the least. Base: N= 8,000. Numbers shown are
percentages.
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Table 3. Asthma control and indicators of symptoms and exacerbations by treatment level
Reliever only
(n= 1,419)
Single-drug preventer
inhaler (n= 1,923)
Combination preventer
inhaler (n= 754)
Combination preventer inhaler
plus oral pill (n=234)
Control and indicators of symptoms
GINA-deﬁned control level
Controlled 408 (28.8) 465 (24.2) 165 (21.9) 40 (17.1)
Partially controlled 594 (41.9) 700 (36.4) 278 (36.9) 79 (33.8)
Uncontrolled 417 (29.4) 758 (39.4) 311 (41.2) 115 (49.1)
Normal activities affected by symptomsa
None 732 (51.6) 986 (51.3) 387 (51.3) 92 (39.3)
⩾ 1 day 687 (48.4) 937 (48.7) 367 (48.7) 142 (60.7)
⩾ 3 days 187 (13.2) 318 (16.5) 160 (21.2) 67 (28.6)
Days with symptomsa
None 370 (26.1) 417 (21.7) 164 (21.8) 37 (15.8)
⩾ 1 day 1,049 (73.9) 1,506 (78.3) 590 (78.2) 197 (84.2)
⩾ 3 days 389 (27.4) 724 (37.6) 340 (45.1) 115 (49.1)
Night-time awakeninga
None 801 (56.4) 1,045 (54.3) 392 (52.0) 114 (48.7)
⩾ 1 day 618 (43.6) 878 (45.7) 362 (48.0) 120 (51.3)
Reliever inhaler usea
Not used 540 (38.1) 559 (29.1) 208 (27.6) 53 (22.6)
⩾ 1 times 871 (61.4) 1,297 (67.4) 501 (66.4) 172 (73.5)
⩾ 3 times 430 (30.3) 786 (40.9) 326 (43.2) 112 (47.9)
⩾ 10 times 38 (2.7) 139 (7.2) 64 (8.5) 23 (9.8)
Acute exacerbations
Antibiotic use for an asthma-associated conditionb
0 698 (49.2) 860 (44.7) 334 (44.3) 69 (29.5)
⩾ 1 course 721 (50.8) 1,063 (55.3) 420 (55.7) 165 (70.5)
Oral steroid use for worsening asthmab
0 1,049 (73.9) 1,362 (70.8) 455 (60.3) 86 (36.8)
⩾ 1 course 370 (26.1) 561 (29.2) 299 (39.7) 148 (63.2)
Emergency department visit due to asthmab
0 1,243 (87.6) 1,650 (85.8) 614 (81.4) 164 (70.1)
⩾ 1 visit 176 (12.4) 273 (14.2) 140 (18.6) 70 (29.9)
Overnight hospitalisation due to asthmab
0 1,369 (96.5) 1,843 (95.8) 696 (92.3) 194 (82.9)
⩾ 1 stay 50 (3.5) 80 (4.2) 58 (7.7) 40 (17.1)
Data are shown as n (%) of patients. Only patients with an identiﬁable treatment were included.
Abbreviation: GINA, Global Initiative for Asthma.
aIn the previous 7 days.
bIn the previous 12 months.
Table 4. Patients’ perceptions of their asthma
GINA-deﬁned asthma control
Overall (N= 8,000) Controlled
(n= 1,604)
Partially controlled
(n= 2,785)
Uncontrolled
(n= 3,611)
Respondents who agree with the following statements, n (%)
Don't label me as a person who is sicka 6,558 (82.0) 1,400 (87.3) 2,322 (83.4) 2,836 (78.5)
My symptoms are not seriousa 5,730 (71.6) 1,412 (88.0) 2,239 (80.4) 2,079 (57.6)
I am not like other people with asthmaa 4,982 (62.3) 1,112 (69.3) 1,800 (64.6) 2,070 (57.3)
I am in better health than other people my age/I have a
similar level of health to other people my ageb
5,647 (70.6) 1,323 (82.5) 2,057 (73.9) 2,267 (62.8)
I ignore my asthma and its symptoms so I can feel normal
and ﬁt in with my friends/peersa
3,420 (42.8) 622 (38.8) 1,197 (43.0) 1,601 (44.3)
Abbreviation: GINA, Global Initiative for Asthma.
aResponses were combined for ‘tend to agree’ and ‘strongly agree’.
bResponses to both statements were combined.
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said they would also use online sources—including search
engines (43.6%), speciﬁc disease- or health-related websites
(30.0%) and social media such as Facebook (4.1%) and
Twitter (1.5%).
DISCUSSION
Main ﬁndings
Overall, these data from the REALISE survey indicate that the level
of GINA-deﬁned asthma control remains low, with only one-ﬁfth of
respondents having controlled asthma. The incidence of symptoms
and acute exacerbations was high; almost half of the respondents
reported that they had required oral steroids for asthma in the
previous year and almost one-quarter had visited the emergency
department. Indeed, many respondents whose asthma was
Table 5. Patients’ perceptions of asthma control for the overall population and by GINA-deﬁned control levels and exacerbations
GINA-deﬁned asthma control Acute exacerbationsa
Overall (N=8,000) Controlled
(n= 1,604)
Partially
controlled
(n=2,785)
Uncontrolled
(n= 3,611)
Oral steroid
(n=3,516)
Emergency
department visits
(n=1,910)
Hospitalisations
(n=934)
Perception of asthma control
Not
controlled
757 (9.5) 42 (2.6) 127 (4.6) 588 (16.3) 417 (11.9) 288 (15.1) 164 (17.6)
Controlled 7,243 (90.5) 1,562 (97.4) 2,658 (95.4) 3,023 (83.7) 3,099 (88.1) 1,622 (84.9) 770 (82.4)
Perception of asthma seriousness
Not serious 6,682 (83.5) 1,572 (98.0) 2,587 (92.9) 2,523 (69.9) 2,636 (75.0) 1,300 (68.1) 541 (57.9)
Serious 1,318 (16.5) 32 (2.0) 198 (7.1) 1,088 (30.1) 880 (25.0) 610 (31.9) 393 (42.1)
Concern about asthma
Not
concerned
5,992 (74.9) 1,532 (95.5) 2,354 (84.5) 2,106 (58.3) 2,240 (63.7) 1,108 (58.0) 477 (51.1)
Concerned 2,008 (25.1) 72 (4.5) 431 (15.5) 1,505 (41.7) 1,276 (36.3) 802 (42.0) 457 (48.9)
Data are shown as n (%) of patients.
Abbreviation: GINA, Global Initiative for Asthma.
aAt least one in the previous 12 months due to asthma.
I take it every day
I take it some days,
but others I do not
I used to take it,
but now I do not
I take it only when
I have symptoms
I never take it
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Figure 3. Daily use of preventer medication. Q: Which statement
best describes how you take your regular asthma treatment? This is
your preventer inhaler, which is usually brown, orange or red. Base:
respondents taking a preventer inhaler (overall: n= 3,481; Global
Initiative for Asthma-deﬁned controlled: n= 620; partially controlled:
n= 1,171; uncontrolled: n= 1,690).
I find it a real nuisance having
to use my inhaler
I feel embarrassed using my
inhaler in front of others
I feel embarrassed carrying
my inhaler with me
I find my inhaler
difficult to use
41
29
36
50
36
24
30
46
26
13
19
37
14
5
9
23
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Respondents (%)
Overall
Controlled
Partially controlled
Uncontrolled
Figure 4. Respondents’ attitudes towards their inhaler. Q: To what
extent do you agree with the following statements? Data shown for
strongly agree plus tend to agree. Base overall: n= 8,000; Global
Initiative for Asthma-deﬁned controlled: n= 1,604; partially con-
trolled: n= 2,785; uncontrolled: n= 3,611.
REcognise Asthma and LInk to Symptoms and Experience
D Price et al
6
npj Primary Care Respiratory Medicine (2014) 14009 © 2014 Primary Care Respiratory Society UK /Macmillan Publishers Limited
controlled at the time of the survey according to the GINA criteria
reported a history of acute exacerbations over the previous year.
Most respondents did not recognise symptoms as indicators of
poor control, suggesting a continuing disconnection between
patients’ perceptions of control and guideline-deﬁned control.
Strengths and limitations of this study
The REALISE survey is one of the largest surveys of patients’
attitudes to asthma and its management in Europe to date,
conducted in a population using the Internet and social media. As
for any survey of this kind, however, there are some limitations.
The main aim of REALISE was to provide a broad view of asthma
control and patient attitudes across Europe as a whole. All data
were analysed for the whole study population; however, there was
some country-speciﬁc variation among respondents from the
different countries included.22 All data were reported by the
respondents and could not be clinically veriﬁed, and inaccurate
responses due to poor recall cannot be excluded. This survey
assessed patients aged 18–50 years who used social media, and
this group may not be fully representative of the wider patient
population. This study was not designed to compare asthma
control among respondents who use social media with those who
do not; it might be interesting to observe any effect of social
media on asthma management in future surveys. The mean age of
respondents is lower than that of patients with asthma in previous
European appraisals in clinical practice, such as the European
National Health and Wellness Survey.5,23 We believe, however,
that the REALISE respondent population is broadly consistent with
asthma populations reported in other studies. The proportion of
females was comparable to those reported elsewhere (including
the European Community Respiratory Health Survey and Asthma
Insights and Reality in Europe),5,19,23,24 as were the proportions
of current smokers and respondents prescribed controller
medication.5,23 Moreover, the reported incidences of emergency
department visits and hospitalisations due to asthma were similar
to those in the National Health and Wellness Survey.5
Co-morbidities were self-reported by respondents and not
clinically veriﬁed. We sought to compare the levels of
co-morbidities with other, comparable survey populations, but
these were frequently not reported.5,17–19,22 Overall, the level of
self-reported co-morbidities was relatively high, especially for a
young population. Depression was the most frequent co-
morbidity among REALISE respondents (prevalence, 13.5%),
although this was observed to a greater degree in the Health
and Wellbeing Study (21–29%).5 In the present survey, respon-
dents were recruited from different consumer panels and, in some
cases, through press advertising; however, this is unlikely to have
introduced systematic bias.
Interpretation of ﬁndings in relation to previously published work
Overall, the ﬁndings of REALISE are in agreement with previous
initiatives. Our present survey offers the largest pan-European
appraisal of GINA-deﬁned control, incidence of symptoms and
exacerbations, and insights into patient attitudes and under-
standing of the disease (Table 6). The observed incidences of
uncontrolled asthma and symptoms are broadly consistent
with those reported in previous surveys of patients with
asthma,7,16–20,25 underlining the validity of this study. In a recent
European survey, 54% of patients had asthma that was not well
controlled,5 compared with 45% of respondents with uncontrolled
asthma in the present survey. In the 2005 International Asthma
Patient Insight Research survey, conducted in a population using
combination therapy, the rate of uncontrolled asthma was
51%.7 Notably, in the current survey, the proportion of patients
in the corresponding subset (those prescribed a combination
preventer inhaler) with uncontrolled asthma was lower (41%),
suggesting that, although asthma control remains low overall,
there may have been a slight improvement in recent years.7
Patients using the Internet may beneﬁt from access to online
information sources about asthma. Interestingly, a study has
shown that asthma control may be improved by online self-
management strategies—including the monitoring of control,
treatment advice and online education.26
Implications for future research, policy and practice
Frequent reliever inhaler use was notable; more than 40% of
respondents had used their reliever three or more times in the
previous week, and frequent use (⩾10 times in the previous week)
was highest in those prescribed a combination preventer inhaler.
This may reﬂect high levels of uncontrolled asthma, but could also
0 20 10010 30 40 6050 70 80 90
Respondents (%)
HCP (combined)
Family doctor
Specialist respiratory doctor
Pharmacist
Nurse
Online sources (combined)
A search engine (e.g., Google, Bing, Yahoo etc.)
Specific disease or health websites
Online health forums
Pharmaceutical companies via their website
Facebook
Twitter
YouTube
Friends and family (combined)
Family
Friends
Magazines, TV or radio
Other
None – I don't look for information
79
59
46
24
13
61
44
30
22
7
4
2
2
25
18
17
8
2
5
Figure 5. Sources of information about asthma. Q: If you were to look for information about asthma, which of the following would you use?
Combined= all respondents who selected at least one answer from the list of possible options. Base: N= 8,000.
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indicate an over-reliance on rescue medication, suggesting that
patients do not recognise reliever use as a sign of deteriorating
asthma and that their medication may require adjustment.7
Our survey also found a high incidence of oral steroid use,
emergency department visits and hospitalisations over the
12 months before the survey, even among those whose asthma
was controlled at the time of the survey. These indicators are
consistent with the American Thoracic Society/European Respira-
tory Society Statement deﬁnition of severe exacerbations in
clinical trials,27 demonstrating that exacerbations in clinical
practice remain common and are a serious concern. Currently
controlled asthma does not preclude future exacerbations.
Accordingly, in addition to a patient’s current level of symptoms
and asthma control, it is important to assess their exacerbation
risk.9 Indeed, international guidelines state that the joint aims of
asthma management should be to achieve asthma control and
reduce exacerbation risk. Our ﬁndings may suggest a need to
improve the assessment of control and patients’ risk for future
exacerbations.
GINA guidelines recommend a stepwise approach to asthma
management.2 The proportion of respondents with uncontrolled
asthma was high across all treatment levels, which may indicate
under-use, inappropriate use or under-prescription of therapies;
this highlights the need for HCPs to supervise treatment use more
closely, provide hands-on advice and guidance, and empower
patients through education to achieve better self-management of
their asthma.
The data also provide insights into patient attitudes to asthma
and its treatment. Most respondents did not want to be labelled
as sick; the majority also regarded their asthma as controlled and
not serious, even among respondents with uncontrolled asthma,
highlighting a disconnection between patients’ perceptions of
their asthma and guideline-deﬁned levels of control. This
disconnect has been reported before, and it is worrying that
there has been little apparent improvement;6,19,20,28 in a previous
survey, up to half of the patients with severe persistent symptoms
considered their asthma to be controlled.6,19
These ﬁndings together show a need to ensure that asthma is
accurately assessed in clinical practice, and to improve patients’
understanding so that symptoms and exacerbations are recog-
nised and acted upon. The disconnection between patient-
perceived and guideline-deﬁned control may be partly due to
different aspirations of patients and HCPs, as well as different
deﬁnitions of ‘control’ between patients and variations in
assessments from clinical questionnaires. For patients, asthma
control may be most easily understood as managing exacerbation
risk, rather than as achieving a predeﬁned threshold of symptom
control. In addition, successful asthma management requires a
good partnership between patients and HCPs;28 a shared
language and understanding is vital. Training HCPs in
patient-centred communication skills can help optimise asthma
management in primary care.29
In clinical practice, prescriptions are often initiated based on
limited information gained from short conversations during
consultations. However, asthma control should be assessed using
standardised tools such as the Asthma Control Questionnaire or
the Asthma Control Test, which can potentially improve the
assessment of control in a reproducible, objective way.2
Non-adherence and poor inhaler technique are associated with
suboptimal asthma control.30–32 It is concerning that ~ 50% of
respondents reported that they did not take their maintenance
therapy as prescribed, and fewer than half had had their inhaler
technique checked by an HCP in the previous year. Many patients
frequently use their inhaler incorrectly;33–35 however, training can
improve control. In a recent study, the proportion of patients with
optimal inhaler technique rose from 24 to 79% following training,
leading to signiﬁcant increases in asthma control scores.36 For
effective instruction the trainer must also be competent in using
the device;30 unfortunately, some HCPs are not aware of optimal
inhaler technique.37
Table 6. Other European surveys and studies of patients with asthma
Study name Number of
countriesa
Number of
patients
Age, years Survey design Prevalence of
uncontrolled
asthma
Experienced
symptoms
Rescue medication
use
European National
Health and Wellness
Survey5 (2010 data)
5 3,848 18 and above Repeated cross-
sectional survey
54% (‘not well-
controlled’)
NR as percentage
of patients
~ 75% >2 times
per week (not well-
controlled
population)
The Living and
Breathing study20
1 517 14–65 Quantitative face-
to-face interview
NR 66% (>2 times
per week)
32% daily
Global Asthma
Insights and Reality
Survey16
7 2,803 Children (o16)
and adults
Telephone
questionnaire
NR 56% (in the
previous 4 weeks)
NR
International
Control of Asthma
Symptoms17
7b 802 16 and above Computer-aided
telephone
interview
82% (‘absence of
control’)
74% (in the
previous 8 weeks)
62% (>1 use in the
previous 8 weeks)
Asthma Insight and
Management in
Europe and Canada
(EUCAN AIM)
survey25
5 2,019 Adolescents
(12–17) and adults
Telephone
interview
12–35%c 13–29%c (every
day or most days
in the previous
4 weeks)
31–56%c (>1 use
per week, over the
past year)
UK asthma survey38 1 1,083 18 and above Online
questionnaire
survey
NR 65% (in the
past 2 years)
41% (⩾1/day)
Understanding
patients with
asthma and COPD18
5 1,022 18 and above Online
questionnaire
survey
38% (ACQ >1.5) NR 58% (>1–2 most
days)
Abbreviations: ACQ, Asthma Control Questionnaire; COPD, chronic obstructive pulmonary disease; NR, not reported.
aUnless otherwise speciﬁed, only European countries are included in this table.
bIncludes Canada and Australia.
cRange across all countries.
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The Internet may support patient self-management of chronic
conditions.26 Notably, over half of the respondents in the present
survey stated that they would use online sources for information
about their asthma; providing patients with access to reliable
websites may thus increase their level of understanding and help
improve asthma control.18,26
This report presents the ﬁrst set of results from the REALISE
survey. The large size of the population (which included 240–1,024
respondents from each country) and the diversity of the
participating countries support further analyses, including assess-
ment of variations in asthma control and treatment across the
countries. The survey also gathered a large amount of novel
information on patients’ attitudes to asthma. This could be used to
analyse patients’ behaviour and attitudes to online sources for
information about asthma; the data will be explored to determine
whether different patient types exist and whether such informa-
tion could help develop tailored asthma management strategies.
CONCLUSIONS
Asthma control in Europe remains poor, and symptoms and
exacerbations are common across all treatment levels. Many
patients with asthma do not regard themselves as sick and are not
concerned about their condition, believing it to be controlled;
many individuals do not associate symptoms with poor control.
Hence, there remains a marked discrepancy between patient-
perceived and guideline-deﬁned asthma control. There is a clear
need to assess patients’ control, risk and inhaler technique, and to
ensure that they are prescribed, and take, appropriate treatments.
Educating patients will help improve their understanding of
asthma and enable them to work with their HCP to manage their
disease.
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